Tercica (TRCA) Reports Results from Increlex(R) IGFD Patient Registry
More News related to TRCA
- Tercica (TRCA) Reports Q2 loss of $0.22
- Caxton Associates Accumulates 5.1% Stake in Tercica (TRCA)
- Tercica (TRCA) Reports Results from Increlex(R) IGFD Patient Registry
- Unusual 11 Mid-Day Movers 6/5: TRCA, AERG, SQNM, HOTT Higher; REGN, IDT, WBS, BTH Lower
- Notable Mergers and Acquisitions of the Day 6/5 (VZ, TRCA, BGP)
More News related to Corporate News
- Suncor Energy (SU) Responds to Fire at its Oil Sands Upgrader
- Google (GOOG) Tackles Social Media With "Buzz"
- NV Energy (NVE), Pattern Energy Enter 20-Year Power Purchase Agreement for First Utility-Scale Wind Project in Nevada
- Highlights From PHM's Q4 Conference Call: Expanded Opportunities & Cost Savings From Acquisition of Centex
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
Tercica, Inc. (NASDAQ: TRCA) today announced the first results from the Increlex(R) Growth Forum Database Registry.
Tercica's Vice President, Medical Affairs, Sandra Blethen, said, "Data from the IGFD Registry showed that children treated with Increlex(R) at the higher end of the recommended-dose range (greater than or equal to 100 mcg/kg twice daily) had better growth rates than children treated with lower doses. In addition, these data showed adverse events were not dose-related, and thus emphasize the importance of treating children with severe Primary IGFD using adequate doses of Increlex(R)."
Tercica, Inc., a biopharmaceutical company, engages in the development and marketing of endocrine products.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
